Lantheus appoints Dr. P.K. Morrow to its Board of Directors to enhance oncology expertise and support strategic initiatives.
Quiver AI Summary
Lantheus Holdings, Inc. has announced the appointment of Dr. Phuong Khanh (P.K.) Morrow to its Board of Directors, effective February 1, 2025. Dr. Morrow is a seasoned pharmaceutical executive with significant experience in oncology and will contribute to the Board's Science and Technology Committee. Her expertise in clinical development aligns with Lantheus' mission to enhance patient outcomes through innovative radiopharmaceuticals. The Board will consist of eleven directors, with nine being independent. Lantheus' Chairperson, Mary Anne Heino, expressed enthusiasm about Dr. Morrow's addition, noting her qualifications will support the company's growth during this transformational period. Dr. Morrow currently leads Takeda's oncology R&D strategy and has an extensive background in drug development.
Potential Positives
- Appointment of Dr. Phuong Khanh Morrow, an experienced pharmaceutical executive and physician-scientist, to the Board of Directors enhances Lantheus' leadership team.
- Dr. Morrow’s expertise in oncology and drug development aligns with Lantheus' strategic initiatives and innovation efforts in radiopharmaceuticals.
- The addition of Dr. Morrow marks the second new board appointment in the last five months, signaling ongoing growth and innovation within the company.
- The Board now comprises eleven directors, with nine being independent, which may strengthen governance and strategic oversight.
Potential Negatives
- Appointment of Dr. Morrow as a new board member may indicate recent challenges in leadership or strategy, necessitating multiple appointments within a short timeframe.
- Inclusion of a cautionary note regarding forward-looking statements suggests potential instability or uncertainties within the company's strategic outlook.
- Reliance on independent directors for key decision-making could raise questions about the depth of internal expertise and continuity in leadership direction.
FAQ
Who has been appointed to Lantheus' Board of Directors?
Phuong Khanh (P.K.) Morrow, M.D. has been appointed to Lantheus' Board of Directors effective February 1, 2025.
What is Dr. Morrow's expertise?
Dr. Morrow has extensive experience in oncology and pharmaceutical clinical development, leading end-to-end clinical programs.
How many directors are on Lantheus' Board?
Following Dr. Morrow's appointment, Lantheus' Board comprises eleven directors, nine of whom are independent.
What notable positions has Dr. Morrow held?
Dr. Morrow was previously Chief Medical Officer at CRISPR Therapeutics and Vice President at Amgen, overseeing oncology R&D.
What is Lantheus known for?
Lantheus is a leading radiopharmaceutical-focused company dedicated to improving patient outcomes through advanced diagnostics and therapeutics.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LNTH Insider Trading Activity
$LNTH insiders have traded $LNTH stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $LNTH stock by insiders over the last 6 months:
- MARY ANNE HEINO has made 0 purchases and 7 sales selling 21,968 shares for an estimated $2,002,117.
- GERARD BER has made 0 purchases and 3 sales selling 15,500 shares for an estimated $1,495,395.
- ROBERT J. JR. MARSHALL (CFO and Treasurer) sold 10,000 shares for an estimated $812,000
- PAUL BLANCHFIELD (President) has made 0 purchases and 2 sales selling 4,000 shares for an estimated $352,080.
- DANIEL NIEDZWIECKI (See Remarks) sold 2,500 shares for an estimated $243,850
- JAMES H THRALL has made 0 purchases and 2 sales selling 2,000 shares for an estimated $193,280.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$LNTH Hedge Fund Activity
We have seen 248 institutional investors add shares of $LNTH stock to their portfolio, and 244 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 1,237,013 shares (+103.7%) to their portfolio in Q3 2024, for an estimated $135,762,176
- SILVERCREST ASSET MANAGEMENT GROUP LLC removed 1,049,960 shares (-60.0%) from their portfolio in Q3 2024, for an estimated $115,233,110
- LAZARD ASSET MANAGEMENT LLC added 688,688 shares (+174.7%) to their portfolio in Q3 2024, for an estimated $75,583,508
- FARALLON CAPITAL MANAGEMENT LLC added 676,000 shares (+29.7%) to their portfolio in Q3 2024, for an estimated $74,191,000
- MILLENNIUM MANAGEMENT LLC removed 522,976 shares (-70.0%) from their portfolio in Q3 2024, for an estimated $57,396,616
- MACQUARIE GROUP LTD removed 479,852 shares (-34.8%) from their portfolio in Q3 2024, for an estimated $52,663,757
- INVESCO LTD. added 455,396 shares (+27.0%) to their portfolio in Q3 2024, for an estimated $49,979,711
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus’ Board of Directors (“Board”), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board’s Science and Technology Committee, where her proven track record in advancing clinical programs and wealth of knowledge in oncology therapeutics development will help guide the success of Lantheus’ strategic initiatives and innovation efforts. Following her appointment, the Board will be comprised of eleven directors, nine of whom are independent.
“Lantheus is excited to welcome P.K. Morrow to our Board of Directors – the second new board appointment in the past five months – during this pivotal period of growth and innovation in radiopharmaceuticals,” said Mary Anne Heino, Chairperson of the Board. “Dr. Morrow’s extensive expertise in drug development and her significant experience in oncology align well with our vision for the future of Lantheus and will be essential in our Purpose to Find, Fight and Follow disease to deliver better patient outcomes."
“I look forward to joining the Lantheus Board and partnering with a dedicated team of patient-centric leaders who are focused on advancing the Company’s research and development capabilities to support its innovative pipeline,” said Dr. Morrow. “With a strong legacy in precision diagnostics and radiopharmaceuticals and the recent announcement of two strategic deals, I am confident that Lantheus is well-positioned to continue its growth as a fully integrated radiopharmaceutical company, while making an impact on the lives of patients with difficult-to-treat disease.”
Dr. Morrow is currently the Head of the Oncology Therapeutic Area Unit (OTAU) at Takeda, where she is responsible for the company’s oncology R&D strategy and development portfolio. Prior to joining Takeda, Dr. Morrow served as Chief Medical Officer at CRISPR Therapeutics, where she led a cross-functional team of physicians, scientists and development team members, overseeing end-to-end development of clinical programs spanning hematology, oncology, diabetes and cardiovascular diseases states. Dr. Morrow previously spent over a decade at Amgen, where she served as Vice President and Global Therapeutic Area Head of Hematology, GI Oncology, GU Oncology, and Bone Diseases. Before joining the industry, she held the role of Assistant Professor, Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center. Dr. Morrow received an M.D. from the University of Texas Medical School at Houston. She completed her internal medicine residency at Baylor College of Medicine and a Hematology/Oncology Fellowship at the University of Texas MD Anderson Cancer Center, where she received the Clifton D. Howe (Fellow of the Year) Award, the American Society of Clinical Oncology Young Investigator Award, and served as the Lyndon Baines Johnson Chief Fellow.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit
www.lantheus.com
.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as “continue,” “execute,” “will” and other similar terms. Such forward-looking statements are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements are discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).
Contacts:
Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
[email protected]
Melissa Downs
Senior Director, External Communications
646-975-2533
[email protected]